SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0268 3369 "

Sökning: L773:0268 3369

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Abelsson, J., et al. (författare)
  • The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
  • 2012
  • Ingår i: Bone Marrow Transplantation. - : Nature Publishing Group. - 1476-5365 .- 0268-3369. ; 47:3, s. 380-386
  • Tidskriftsartikel (refereegranskat)abstract
    • Between 1982 and 2009 a total of 92 patients with myelofibrosis (MF) in chronic phase underwent allo-SCT in nine Nordic transplant centers. Myeloablative conditioning (MAC) was given to 40 patients, and reduced intensity conditioning (RIC) was used in 52 patients. The mean age in the two groups at transplantation was 46 +/- 12 and 55 +/- 8 years, respectively (P<0.001). When adjustment for age differences was made, the survival of the patients treated with RIC was significantly better (P=0.003). Among the RIC patients, the survival was significantly (P=0.003) better for the patients with age <60 years (a 10-year survival close to 80%) than for the older patients. The type of stem cell donor did not significantly affect the survival. No significant difference was found in TRM at 100 days between the MAC-and the RIC-treated patients. The probability of survival at 5 years was 49% for the MAC-treated patients and 59% in the RIC group (P=0.125). Patients treated with RIC experienced significantly less aGVHD compared with patients treated with MAC (P<0.001). The OS at 5 years was 70, 59 and 41% for patients with Lille score 0, 1 and 2, respectively (P=0.038, when age adjustment was made). Twenty-one percent of the patients in the RIC group were given donor lymphocyte infusion because of incomplete donor chimerism, compared with none of the MAC-treated patients (P<0.002). Nine percent of the patients needed a second transplant because of graft failure, progressive disease or transformation to AML, with no significant difference between the groups. Our conclusions are (1) allo-SCT performed with RIC gives a better survival compared with MAC. (2) age over 60 years is strongly related to a worse outcome and (3) patients with higher Lille score had a shorter survival. Bone Marrow Transplantation (2012) 47, 380-386; doi:10.1038/bmt.2011.91; published online 9 May 2011
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  • Al Hashmi, S., et al. (författare)
  • Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion
  • 2013
  • Ingår i: Bone Marrow Transplantation. - 0268-3369 .- 1476-5365. ; 48:6, s. 843-848
  • Tidskriftsartikel (refereegranskat)abstract
    • Omega-3 is known to enhance the effects of several chemotherapeutic agents and to exert several immunoregulatory actions In the present study, we evaluated the effects of a 21-day feeding regimen with omega-3-rich fish oil (FO) and its corresponding control, omega-6 rich corn oil (CO), on the BU-CY conditioning and the development of GVHD after BMT in mice. Before conditioning, FO, but not CO, feeding caused a significant attenuation in the number and functionality of splenic FoxP3+ T regulatory cells (Treg). FO feeding also enhanced the effects of the conditioning through severe depletion of Treg cells in the spleen and CD11b+ myeloid cells in both the BM and spleen. Consequently, FO-fed animals conditioned with BU-CY showed exacerbated GVHD following transplantation with allogeneic BM and splenic cells. In contrast, identical transplantation in CO-fed mice resulted in poor engraftment and body weight loss. Moreover, in standard-fed recipients, BMT with cells from FO-fed donors resulted in moderate GVHD and improved the survival time, whereas BMT with cells from CO-fed donors shortened the survival time and caused anemia. We conclude that food supplements should be considered in patients undergoing BMT and/or chemotherapy treatment.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
konferensbidrag (367)
tidskriftsartikel (246)
forskningsöversikt (1)
Typ av innehåll
övrigt vetenskapligt (395)
refereegranskat (219)
Författare/redaktör
Ringden, O (239)
Ljungman, P (195)
Remberger, M. (164)
Mattsson, J. (143)
Hagglund, H (56)
Winiarski, J (54)
visa fler...
Aschan, J (46)
Hassan, M (45)
Gahrton, G (41)
Uzunel, M (39)
Uhlin, M. (37)
Hassan, Z. (35)
Le Blanc, K (33)
Barkholt, L (29)
Bjorkstrand, B (27)
Niederwieser, D (27)
Volin, L (27)
Lonnqvist, B (24)
Brune, M. (22)
Omazic, B (22)
Kroger, N (22)
Svahn, BM (22)
Sadeghi, B (21)
Gustafsson, B. (21)
Hentschke, P (21)
Labopin, M (21)
Iacobelli, S (21)
Sundin, M. (20)
Sundberg, B. (19)
Sparrelid, E (19)
Morris, C (18)
Michallet, M (18)
Nava, S (17)
Garderet, L (17)
de Witte, T (17)
Gratwohl, A (17)
Lenhoff, S. (16)
Cordonnier, C. (16)
Machaczka, M (16)
Socie, G (16)
Johansson, E (15)
Blaise, D (15)
Nilsson, C (14)
van Biezen, A (14)
Finke, J. (13)
Olsson, R (13)
Hauzenberger, D (13)
Carlson, K (13)
Carlens, S (13)
Frassoni, F (13)
visa färre...
Lärosäte
Karolinska Institutet (551)
Uppsala universitet (58)
Linköpings universitet (14)
Göteborgs universitet (13)
Lunds universitet (11)
Umeå universitet (4)
visa fler...
Stockholms universitet (4)
Kungliga Tekniska Högskolan (3)
Röda Korsets Högskola (3)
Malmö universitet (2)
Sophiahemmet Högskola (2)
Högskolan i Gävle (1)
Ersta Sköndal Bräcke högskola (1)
Högskolan Dalarna (1)
visa färre...
Språk
Engelska (614)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (65)
Naturvetenskap (3)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy